CliffBio
small molecule

AZELEX

AZELAIC ACID

Loss of exclusivity—loss of exclusivity
CompanyAlmirall →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZELEX
Active ingredientAZELAIC ACID
Strength20%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalSeptember 1995
Marketing statusRX

More from Almirall

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AZELEX patent cliff — loss of exclusivity — | CliffBio